
COVIDã¯ã¯ãã³æ¥çš®1幎åŸãè¥å¹Žæäººã¯ã¹ãã€ã¯ã»ãããã€ã³ãç£çãç¶ãã
å èšäºã¯ãã¡ããã/Click here to read the original article.
å é±ã**ãImmunity, Inflammation and Diseaseã**ã«æ²èŒãããæ»èªæžã¿ã®ç ç©¶ã¯ãmRNAåCOVID-19ã¯ã¯ãã³ãäºæ³ä»¥äžã«é·æéã«ãããäœå ã§ã¹ãã€ã¯ã¿ã³ãã¯è³ªãçæãç¶ããå ç«ã·ã¹ãã ã®èª¿æŽäžå šãåŒãèµ·ããå¯èœæ§ããããšãããç§åŠç蚌æ ãå¢ããŠããããšã瀺ããŠããŸãã
ãã¡ã€ã¶ãŒè£œCOVID-19ã¯ã¯ãã³ãæ¥çš®ããè¥å¹Žå±€ããã¯ã¯ãã³æ¥çš®ãã1幎以äžçµéããåŸãã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çæãé«ãã¬ãã«ã§ç¶ããŠããããšããæ»èªæžã¿ã®ç ç©¶ã§ç€ºãããŸããã ããã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãäœå ã«çãŸãäºæ³ãããããªãé·ãæéã«ããã£ãŠç¶ãããšã瀺ããŠããŸãã
ãã®ç ç©¶ã¯ãå é±**ãImmunity, Inflammation and Diseaseãã«æ²èŒãããåå è ãè€æ°ã®ççä¿é²æ§ãµã€ãã«ã€ã³ïŒå ç«ã·ã¹ãã ã®èª¿ç¯ã«é¢ããã¿ã³ãã¯è³ªïŒã®ã¬ãã«ãé«ãããšã瀺ãããmRNAã¯ã¯ãã³ãžã®äœæ¶²å ç«åå¿ã®æç¶ãã瀺åããŠãã**ããšãåãããŸããã
ç ç©¶ã«ãããšããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®æç¶çãªçæãšmRNAãªãããããç²åã®é«ãççæ§ããããµã€ãã«ã€ã³ã¬ãã«ã®äžæã®åå ãšãªãå¯èœæ§ããããšãããŠããŸãã
ãªãããããç²åã¯ãmRNAã人éã®çްèã«å±ããããšãç®çãšããŠããŸãããããããããã¯mRNA COVID-19ã¯ã¯ãã³ã«å«ãŸããDNAæ±æç©è³ªãäœå ã«åºããããšã確èªãããŠããŸãã
ç ç©¶ã¯COVIDã¯ã¯ãã³ã®é·æçãªåœ±é¿ã«é¢ããéèŠãªè³ªåãæèµ·
ããã®ç ç©¶ã¯ãå¥åº·ãªè¥å¹Žæäººã«ãããmRNA COVID-19ã¯ã¯ãã³ã®é·æçãªå ç«çå»å°ã«é¢ããéèŠãªè³ªåãæèµ·ããŠããŸãããšTrialSite Newsã¯å ±ããŸããã
TrialSite Newsã®åµèšè ã§CEOã®ãããšã«ã»ãªã³ããŒæ°ã¯ããã®ç ç©¶ã®çµæããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®é€å»ãšãã€ãªååžã«é¢ããç ç©¶ã®ç·æ¥ã®å¿ èŠæ§ãæµ®ã圫ãã«ããŠãããç¹ã«è¥ãç·æ§ãé«éœ¢è ã«ãããŠå ç«åå¿ãäžåè¡¡ã«åœ±é¿ãåããŠããããšã瀺ãããŠããŸãããšè¿°ã¹ãŸããã
**Children's Health Defense (CHD)**ã®ã·ãã¢ç ç©¶å¡ã§ããã«ãŒã«ã»ãžã£ããããŠã¹ããŒå士ã¯ãç ç©¶ã®ãã¶ã€ã³ããã³ã³ãããŒã«çŸ€ããªã84人ã察象ã«ãã瞊æçç ç©¶ã§ãããããæåŒ·ã®ãã¶ã€ã³ãšã¯èšããªãããšææãã€ã€ãããã®ç ç©¶ãã匷ã瀺åãæã€èšŒæ ã瀺ããŠããããšè¿°ã¹ãŸããã
ãžã£ããããŠã¹ããŒå士ã¯ããæ°ã¶æãããã«ã¯æ°å¹Žã«ãããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çæã«ã¯æ¬åœã«æãããå¯èœæ§ãããããã®äžã€ã¯T现èã®æ¶èã§ãããšèšããŸãããããã«ãããäœããŠã€ã«ã¹ãçãšå¹æçã«æŠããªããªãå¯èœæ§ããããŸãããæåãžã®æç¶çãªæé²ã¯T现èãæ¶èããããã®èªç¶ãªæ©èœãæå¶ããŸãããšè¿°ã¹ãŸããã
ç«åŠè ã®ãã³ã©ã¹ã»ãã«ã·ã£ãŒæ°ã¯ããã®ç ç©¶çµæã¯ãäºæããããã®ã§ããããšè¿°ã¹ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã®æç¶çãªååšã人äœã«äžãã圱é¿ã瀺ãã130ã®æ»èªæžã¿ç ç©¶ãæããŸããã
ãã«ã·ã£ãŒæ°ã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãžã®é·æçãªæé²ããé·åŒãCOVIDãšèšºæããã人ã ãçµéšããçç¶ã«äŒŒãçç¶ãåŒãèµ·ããå¯èœæ§ããããšè¿°ã¹ãŸããã
ã€ãšãŒã«å€§åŠã®ç ç©¶è ãã¡ã«ããäºåå ¬éè«æïŒ2025幎2æçºè¡šïŒã§ã¯ãé·åŒãCOVIDãšèããããŠãã人ã ãå®éã«ã¯ãã¯ã¯ãã³æ¥çš®åŸçå矀ãã«èŠããã§ããå¯èœæ§ãããããšã瀺ãããŸããããã®ç ç©¶ã§ã¯ãCOVID-19ã¯ã¯ãã³ããã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªããæ¥çš®åŸ709æ¥çµã£ãŠãå°ãªããšãäžäººã®è¡æ¶²ã«æç¶ããŠããããšã瀺ãããŠãããããã¯ãããŸã§ã«æž¬å®ãããæéãããããªãé·ãæéã§ããã
ãžã£ããããŠã¹ããŒå士ã¯ããã®ç ç©¶çµæãçŸåšç±³åœæ¿åºã®ããŒã¿ããŒã¹ã«ä¿ç®¡ãããŠããCOVID-19ã¯ã¯ãã³ã«ãã被害ããŒã¿ã«é¢ããåºç¯ãªå®å šä¿¡å·ã瀺åããŠããå¯èœæ§ããããšãè¿°ã¹ãŸããã
ãããã«ã¯ãããå€§èŠæš¡ãªåŸãåãã®ã³ã³ãããŒã«ç ç©¶ãå¿ èŠã§ããããã®ããŒã¿ã¯æ¿åºãå»çæ©é¢ã«ãã£ãŠä¿åãããŠããŸãããšãžã£ããããŠã¹ããŒå士ã¯èšããŸãããããã®çš®ã®ããŒã¿ã¯æ°žé ã«ã¯ä¿æãããŸãããCOVID-19ã¯ã¯ãã³ã®å®³ã«é¢ããæ å ±ãä¿åããããã®æéçãªçªã¯æ¥éã«éãã€ã€ãããŸããã
å æã®ã€ã³ã¿ãã¥ãŒã§ãç±³åœä¿å¥çŠç¥çïŒHHSïŒã®ãããŒãã»Fã»ã±ããã£ã»ãžã¥ãã¢æ°ã¯ãHHSã®äžéšæ©é¢ãæ£è æ å ± â ããããã¯ã¯ãã³ã«ãã被害æ å ±ãå«ãŸãã â ãäºãã«è²©å£²ããŠããããã®æ å ±ãèªç±ã«ã¢ã¯ã»ã¹ã§ããããã«ãããŠããªãããšãæããã«ããŸããã
åãã€ã³ã¿ãã¥ãŒã§ã±ããã£æ°ã¯ã**CDCïŒçŸç äºé²ç®¡çã»ã³ã¿ãŒïŒ**å ã«æ°ããã¯ã¯ãã³è¢«å®³å°éæ©é¢ãèšç«ããããšãçºè¡šããŸããã
èªå·±å ç«çŸæ£ã«é¢é£ãããµã€ãã«ã€ã³ã®ãé¡èãªå¢å ã
æ°ããç ç©¶ã«ãããšãç ç©¶åå è å šäœã§ãäœéãšäœæ Œææ°ïŒBMIïŒã®é¡èãªå¢å ã芳å¯ãããããšãšãã«ããããã€ãã®ãµã€ãã«ã€ã³ã®é¡èãªå¢å ããèŠãããããšã瀺ãããŠããŸãã
Substackã§çºè¡šãããåæã®äžã§ããã«ã·ã£ãŒæ°ã¯ãç ç©¶åå è ã«ãããŠãTNF-αãIL-1βãIL-6ãIL-4ãIL-7ãIL-17E ã®åãµã€ãã«ã€ã³ã®ååšãå¢å ããããšãææããŸããããããã®ãµã€ãã«ã€ã³ã¯ãæ ¢æ§ççãå ç«èª¿æŽã®ç°åžžãããã³èªå·±å ç«ã®æŽ»æ§åã«é¢é£ããŠããããšãããŠããŸãããããã®å¢å ã¯ãç·æ§ã«ãããŠé¡èã«å€§ããã£ãããšç ç©¶ã®èè ãã¡ã¯è¿°ã¹ãŠããŸãã
ãŸããVEGFAïŒè¡ç®¡æ°çïŒãFGF2ãIFN-γ ã®ãµã€ãã«ã€ã³ã®å¢å ã芳å¯ããããããã¯ãè¡ç®¡ã®ãªã¢ããªã³ã°ãçµç¹ä¿®åŸ©ãããã³æç¶çãªå ç«æŽ»æ§åã«é¢é£ããŠããããšãããŠããŸããããã«ãMCP-1 ããã³ MCP-3 ã®ãµã€ãã«ã€ã³ãå¢å ãããæ ¢æ§ççãè¡ç®¡ã®ãªã¢ããªã³ã°ãããã³èªå·±å ç«ã«é¢é£ããŠããããšãããŠããŸãã
ç ç©¶ã¯ãŸãããã¯ããã¡ãŒãžã³ãããŒåºæ¿å åïŒM-CSFïŒ ã®ãµã€ãã«ã€ã³ã®ååšãæžå°ããŠããããšã瀺ããŸãããããã¯å ç«ã·ã¹ãã ã®ç°åžžã瀺ããŠããå¯èœæ§ããããšãã«ã·ã£ãŒæ°ã¯èšè¿°ããŠããŸãã
**Childrenâs Health Defense (CHD)**ã®æé«ç§åŠè²¬ä»»è ã§ãããã©ã€ã¢ã³ã»ããã«ãŒå士ã¯ããè¥å¹Žæäººã«ããããµã€ãã«ã€ã³ã®å¢å ã«ã€ããŠã¯ã圌ããç ç©¶å ã§æã倧ããªäœéããã³BMIã®å¢å ãçµéšããããã倿ãé£ããããšè¿°ã¹ãŸããããè¥æºã¯ççãšå¯æ¥ã«é¢é£ããŠããããã§ãããšããã«ãŒå士ã¯ç¶ããŸããã
ããããã幎霢ã®é«ãæäººã®ã³ããŒãã«ãããå¢å ã«ã€ããŠãæžå¿µããããããã¯ãã³ãããã¯äžã®åé¡§çããŒã¿ã䜿çšããããå€§èŠæš¡ã§å æ¬çãªç ç©¶ãå¿ èŠãšããŸãããšããã«ãŒå士ã¯èšããŸãããããã®ããŒã¿ã¯ãç¬ç«ããåæã®ããã«ã§ããã ãæ©ãå ¬éãããã¹ãã§ãããšè¿°ã¹ãŸããã
ç ç©¶ã«ãããšãäœå ã§ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®æç¶ã¯ãmRNAãšççãåŒãèµ·ãããªãããç²åã®ååšã«ãã£ãŠä¿é²ãããããšã瀺ãããŠããŸãããžã£ããããŠã¹ããŒå士ã¯ããããååŠçæ³ãªã©ã®å»çæ²»çã人äœã«äžãã圱é¿ãšæ¯èŒããŸããã
ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã®æç¶çãªçæãå ç«ç³»ã®ã¹ãã¬ã¹ã®åå ã§ãããªãã°ãèªå·±å¢å¹ åmRNA COVID-19ã¯ã¯ãã³ã¯ãã®ã¹ãã¬ã¹ãå¢å€§ãããã ããã
ãæ°ã¶æåŸã«ãµã€ãã«ã€ã³ã®ççæ§ããŒã«ãŒãå¢å ããå»çåŠçœ®ã¯ã»ãšãã©ãããŸããããã®äžã§ãã¢ãžã¥ãã³ãååŠçæ³ã¯ãã®äžã€ã§ãçµç¹ã殺ãããšãç®çãšããæ²»çæ³ã§ãããšãžã£ããããŠã¹ããŒå士ã¯è¿°ã¹ãŸããã
ãžã£ããããŠã¹ããŒå士ã¯ãæè¿æ¥æ¬ã𿬧å·é£åã§æ¿èªãããèªå·±å¢å¹ åmRNA COVID-19ã¯ã¯ãã³ãäœå ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ååšãæªåãããå¯èœæ§ãããããšã瀺åããŸããã
ãè«æã«èšèŒããããµã€ãã«ã€ã³ããŒã«ãŒã¯ãå ç«ç³»ãå§è¿«ãããŠããæç¢ºãªå åã§ããããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®æç¶çãªçæããã®å§è¿«ã®åå ããŸãã¯ãã®äžå ã§ãããªãã°ãæè¿æ¥æ¬ãšãšãŒãããã§æ¿èªãããèªå·±å¢å¹ åCOVID-19 mRNAã¯ã¯ãã³ã¯ãã®å§è¿«ãå¢å¹ ãããã§ãããããšåœŒã¯è¿°ã¹ãŸããã
ããã«ãŒå士ã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ååšãä»ã®å¥åº·ãªã¹ã¯ãåŒãèµ·ããå¯èœæ§ãããããšãææããŸããã
ãççã®å¢å ã¯ãCOVID-19ã¯ã¯ãã³ã«é¢é£ããå€ãã®ç°ãªãç¶æ ãåŒãèµ·ãããŸããããã«ã¯å¿èã®åŸéºçãã¿ãŒãçïŒæ¥éã«é²è¡ããçïŒãå«ãŸããŸããããã¯ãCOVID-19ã¯ã¯ãã³ãåžå Žããå®å šã«æ€éãããã¹ããšããæç®ãæ¯æãã蚌æ ãšããŠæç¢ºã«è²¢ç®ããŠããŸãããšããã«ãŒå士ã¯è¿°ã¹ãŸããã
ãã«ã·ã£ãŒæ°ã¯ããCOVID-19 mRNA泚å°ã«é¢é£ããé倧ãªå®³ãæããã«ãªããã³ã«ãããããåžå Žããå³åº§ã«æ€å»ãã¹ããšãã䞻匵ã¯åŒ·ãŸããããç·æ¥æ§ãå¢ããŠããŸãããšæžããŠããŸãã
ãŸããŸãå€ãã®ç§åŠè«æãç§åŠè ãã¡ã¯ãmRNA補åãåžå Žããæ€éãããã¹ãã ãšèšŽããŠããŸããè€æ°ã®ç§åŠè ã«ããè«é¡æžã¯ãçŸåšFDAã«æåºãããŠãããmRNA COVID-19ã¯ã¯ãã³ã®äžæåæ¢ãŸãã¯æ€éãæ±ããŠããŸããããã€ãã®ã¢ã¡ãªã«ã®å·ãå°å瀟äŒã§ããçŠæ¢ãæ€èšããŠãããšããããããŸãã